0      0

2022 Kaua'i Pain Conference Program

Recognizing & Stratifying Patient Risk for Substance Use Disorder & Other Adverse Effects

Mar 4, 2022 1:45pm ‐ Mar 4, 2022 2:30pm



Over 106,000 physicians and health care professionals are now certified to prescribe buprenorphine in-office—a nearly 70,000 increase since 2017 [SAMHSA, 2021]. Yet, millions with a substance use disorder (SUD) remain without access to evidence-based care.

According to the AMA [2021], physicians must continue to lead, and policymakers must base further action on evidence-based interventions for Substance Use and Pain Care. 


Learning Objectives

As a result of participating in this activity, learners will be able/better able to:

Desirable Physician Attributes

  • Patient Care [ACGME/ABMS] Provide care that is compassionate, appropriate and effective for the treatment of health problems and the promotion of health
  • Medical Knowledge [ACGME/ABMS] about established and evolving biomedical, clinical, and cognate (e.g. epidemiological and social-behavioral) sciences and the application of this knowledge to patient care
  • Employ Evidenced-based Practice [IOM] Integrate best research with clinical expertise and patient values for optimum care, and participate in learning and research activities to the extent feasible

Pain management domains and core competencies

  • 9. Public Health: Lessons learned from the opioid epidemic
    • Describes the impact of pain, opioid use disorder, and other substance use disorders on society

Accreditation & Designation

Neurovations Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Neurovations Education designates this other activity (blended learning) for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Additional Reading

  • Servis, M., Fishman, S. M., Wallace, M. S., Henry, S. G., Ziedonis, D., Ciccarone, D., ... & Willis, B. C. (2021). Responding to the opioid epidemic: educational competencies for pain and substance use disorder from the Medical Schools of the University of California. Pain Medicine, 22(1), 60-66.
  • Ciccarone DH. The triple wave epidemic: Supply and demand drivers of the US opioid overdose crisis. Int J Drug Policy 2019; 71:183–8.Centers for Disease Control and Prevention. CDC advises against misapplication of the Guideline for Prescribing Opioids for Chronic Pain. 2019.
  • Centers for Disease Control and Prevention. CDC advises against misapplication of the Guideline for Prescribing Opioids for Chronic Pain. 2019.
  • Oliva, E. M., Bowe, T., Manhapra, A., Kertesz, S., Hah, J. M., Henderson, P., ... & Trafton, J. A. (2020). Associations between stopping prescriptions for opioids, length of opioid treatment, and overdose or suicide deaths in US veterans: observational evaluation. BMJ, 368.
  • Pilkonis, P. A., Yu, L., Dodds, N. E., Johnston, K. L., Lawrence, S. M., Hilton, T. F., ... & McCarty, D. (2017). An item bank for abuse of prescription pain medication from the patient-reported outcomes measurement information system (PROMIS®). Pain Medicine, 18(8), 1516-1527.
  • Copenhaver DJ, Karvelas NB, Fishman SM. Risk Management for Opioid Prescribing in the Treatment of Patients With Pain From Cancer or Terminal Illness: Inadvertent Oversight or Taboo? Anesth Analg. 2017 Nov;125(5):1610-1615.


You must be logged in and own this session in order to post comments.